Health Care & Life Sciences » Pharmaceuticals | Daehan New Pharm Co. Ltd.

Daehan New Pharm Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
56,702
71,940
90,230
109,403
130,816
Cost of Goods Sold (COGS) incl. D&A
24,229
31,710
38,349
48,277
60,713
Gross Income
32,474
40,231
51,882
61,126
70,103
SG&A Expense
26,367
33,006
41,558
50,001
65,525
EBIT
5,836
6,933
9,980
10,630
4,001
Unusual Expense
-
-
2
11,302
1,737
Non Operating Income/Expense
580
778
771
196
348
Interest Expense
3,780
2,740
2,089
1,550
1,507
Pretax Income
1,783
3,616
7,171
1,990
506
Income Tax
3,738
955
2,516
2,146
21,087
Equity in Affiliates
-
-
507
1,536
-
Consolidated Net Income
1,955
2,661
4,148
5,671
20,581
Net Income
1,955
2,661
4,148
5,671
20,581
Net Income After Extraordinaries
1,955
2,661
4,148
5,671
20,581
Net Income Available to Common
1,955
2,661
4,148
5,671
20,581
EPS (Basic)
139.00
189.00
296.00
404.00
1,466.00
Basic Shares Outstanding
14
14
14
14
14
EPS (Diluted)
139.29
189.62
295.53
404.08
1,466.36
Diluted Shares Outstanding
14
14
14
14
14
EBITDA
7,493
9,079
12,999
14,500
7,194
Other Operating Expense
270
291
343
495
576
Non-Operating Interest Income
307
201
52
37
72
Equity in Affiliates (Pretax)
-
-
-
-
25

About Daehan New Pharm Co.

View Profile
Address
66 Jeyakgongdan 1-gil
Hwaseong-si GY 18622
Korea, Republic Of
Employees -
Website http://www.dhnp.co.kr
Updated 09/14/2018
Daehan New Pharm Co., Ltd. engages in the production of pharmaceuticals and animal health goods. It operates through the pharmaceutical and animal health product business divisions. The pharmaceutical division provides analgesics anti-inflammatory drugs and antipyretics, antibacterial, antidiabetics, antihistamines, antineoplastics and immunosuppressants, cardiovascular drugs, gatrointestinal drugs, muscle relaxants, antispasmodics, cream or ointments and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.